and these cells then initiate inflammatory reactions that lead to tissue destruction. Rituximab is an anti-CD20 monoclonal antibody that suppresses inflammation effectively in autoimmune diseases.

Adverse events after the first infusion were more common among patients in the rituximab group than in the placebo group (93% versus 23%, respectively); the rate of adverse reactions was similar ...

Switching to biosimilars when treating patients with haematological cancers does not increase the risk of adverse events, ...